Humanin
← Back to LibraryOverview
Route(s): Subcutaneous
Typical vial sizes: 10 mg
Dosing window: Anytime
Receptor / target: Mitochondrial Receptors
Properties: Not stated
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 2mg - 5mg twice weekly | Under-researched compared to MOTS-c; dose conservatively. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Protocol logic check
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Active malignancy: Humanin's potent anti-apoptotic mechanisms (Bcl-2 upregulation, Bax inhibition, cytochrome c suppression) that protect healthy cells from death are mechanistically identical to the pathways cancer cells exploit to become chemotherapy-resistant; exogenous Humanin may protect tumor cells from apoptosis-inducing therapy.
- Concurrent cytotoxic chemotherapy: Humanin's anti-apoptotic activity directly opposes the mechanism of action of most chemotherapy agents, which rely on triggering apoptosis in rapidly dividing cells.
- Known hypersensitivity to Humanin or peptide excipients.
- Pregnancy: mitochondrial-encoded peptide signaling in fetal development is not characterized; safety not established.
- Breastfeeding: no data.
- Pediatric use: no safety data.
- Severe cardiac arrhythmia: IGF-1 receptor and STAT3 pathway activation by Humanin may affect cardiac electrophysiology at high doses; limited human data.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Injection site reactions: redness, soreness, mild swelling at subcutaneous injection site; standard peptide injection response; expected and manageable.
- Under-documented adverse effects: Humanin has the least human safety data of any compound in Category IV; all side effect characterization derives from animal studies and early-stage human observation; unknown adverse effects may exist that have not yet been documented.
- Theoretical protection of cancer cells from apoptosis: the mechanistically most significant theoretical adverse effect; Bcl-2 upregulation and Bax inhibition are the same pathways that confer chemotherapy resistance in cancer; not observed as a clinical adverse event but represents the primary safety concern.
- Mild fatigue: reported anecdotally in early weeks of use; possibly related to mitochondrial membrane signaling adjustments.
- Mild headache: uncommon; not well characterized.
- Potential IGF-1 receptor pathway modulation: Humanin signals through the IGF-1 receptor at certain concentrations; theoretical implications for insulin-sensitive conditions warrant monitoring in diabetic subjects.
- No documented endocrine disruption, receptor desensitization, or hormonal suppression in available preclinical literature.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.